Second untreatable superbug infection found in US

Patient in New York infected with a strain of E. coli highly resistant to last-resort antibiotic treatments


A patient in New York has been infected with a strain of E. coli highly resistant to last-resort antibiotic treatments, according to an article on the Becker's Infection Control and Clinical Quality website.

This is the second U.S. patient with the untreatable superbug infection, following a Pennsylvania patient first made public last month.

The mcr-1 gene gives bacteria resistance to colistin, a last-line-of-defense antibiotic used to combat a number of resistant microorganisms.

Going into 2017, the White House has requested $1.1 billion be allocated to efforts to combat antibiotic resistance in the U.S. 

Read the article.

 

 



July 6, 2016


Topic Area: Infection Control


Recent Posts

Hand, Foot and Mouth Disease on the Rise

A number of states are reporting an uptick in HFMD, a highly contagious viral illness that primarily affects infants and young children.


Preparing for the Hazards of Winter Weather

Winter is here and healthcare facilities must be ready for inclement weather to prevent slips and falls.


BayCare Reveals Pagidipati Children's Hospital at St. Joseph's

It is a freestanding facility scheduled to open in 2030.


Why Identity Governance Is Becoming a Facilities Management Issue

As healthcare buildings grow more connected, weak identity controls can expose HVAC, security and other critical systems to serious risk.


Habitat Health Opens South Los Angeles PACE Center

The new center strengthens the local care infrastructure, delivering integrated medical, social and in-home care.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.